Bionano Genomics shares fall 10.88% intraday as revenue declines and market skepticism persists despite bullish growth forecasts.

Bionano Genomics (NASDAQ:BNGO) fell 10.88% intraday as market skepticism over its financial performance and growth prospects weighed on investor sentiment. Recent analysis highlighted a 14% year-over-year revenue decline, contrasting with industry-wide growth, and a price-to-sales (P/S) ratio of 0.5x, significantly lower than peers with P/S ratios exceeding 3.2x. While analysts project 29% annual revenue growth over the next three years, the stock’s depressed valuation suggests investors remain unconvinced, citing concerns over revenue instability and four warning signals in its investment profile, two of which are critical. The market appears discounting the company’s ability to meet lofty growth forecasts, despite its strong historical three-year revenue growth of 11%, leading to a sharp intraday sell-off driven by doubts about near-term execution and risk-adjusted returns.